Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 5;4(3):214-219.
doi: 10.1177/2474126420906395. eCollection 2020 Jun.

Current Best Clinical Practices-Management of Retinal Vein Occlusion

Yasha S Modi  1 , Michael A Klufas  2 , Jayanth Sridhar  3 , Rishi P Singh  4 , Yoshihiro Yonekawa  2 , Paula Pecen  5
Affiliations
Review

Current Best Clinical Practices-Management of Retinal Vein Occlusion

Yasha S Modi et al. J Vitreoretin Dis. .

Abstract

Retinal vein occlusion (RVO) is the second most common cause of vision loss from retinal vascular diseases in adults in the United States. Visual loss arises as a result of a host of factors, including macular ischemia and macular edema. Primary antivascular endothelial growth factor therapy is the current standard of care, with level I evidence demonstrating sustained visual gains up to 2 years after treatment in both branch and central RVO. Prompt antivascular endothelial growth factor therapy is important because delays in treatment yield lesser visual gains. Steroid therapy also improves visual outcomes in RVO but with higher rates of adverse effects, including cataract formation and ocular hypertension. Although the treatment burden can be high, these drugs have collectively revolutionized treatment outcomes in this disease state, providing improved visual outcomes over previous laser therapies.

Keywords: aflibercept; anti-VEGF therapy; bevacizumab; branch retinal vein occlusion; central retinal vein occlusion; dexamethasone implant; intravitreal corticosteroid; macular edema; ranibizumab; retinal vein occlusion; triamcinolone.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Y.S.M. is a consultant for Alimera, Allergan, Genentech, and Novartis. M.A.K. is a consultant for Allergan, Genentech, and Novartis, and a speaker for Genentech. P.P. has nothing to declare. J.S. is a consultant for Alcon, Alimera, and Thrombogenics. R.P.S. is a consultant for Alcon, Novartis, Genentech, Regeneron, Optos, and Zeiss, and performs sponsored research for Apellis. Y.Y. is a consultant for Alcon and Regeneron.

References

    1. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion the beaver dam eye study. Arch Ophthalmol. 2008;126(4):513–518. doi:10.1001/archopht.126.4.513 - PubMed
    1. Hayreh SS. Retinal vein occlusion. Indian J Ophthalmol. 1994;42(3):109–132. - PubMed
    1. Koss MJ, Pfister M, Rothweiler F, et al. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol. 2012;90(2):e98–e103. doi:10.1111/j.1755-3768.2011.02292.x - PubMed
    1. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480–1487. doi:10.1056/NEJM199412013312203 - PubMed
    1. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol. 2001;131(1):61–77. doi:10.1016/s0002-9394(00)00709-1 - PubMed